Pleural Effusions Clinical Trial 20203057

[LCID Study Number: 20203057]

A Phase 2, Randomized, Placebo-controlled, Double-blind, Dose-ranging Study Evaluating LTI-01 (Single-chain Urokinase Plasminogen Activator, scuPA) in Patients With Infected, Non-draining Pleural Effusions

The purpose of this study is to evaluate LTI-01 (single-chain urokinase plasminogen activator, scuPA) in patients with infected, non-draining pleural effusions.

Disease/Condition: Pleural Effusions

Department: Pulmonary and Critical Care

Location(s): Lahey Hospital & Medical Center (Burlington)

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2734

Protocol #: 20203057
Principal Investigator(s): Carla R. Lamb
Study Coordinator(s): Deborah Gannon
Trial Phase: Sponsor Initiated Study Phase 2